Eli Lilly and Co
(XSGO:LLYCL)
CLP
767490
-8430 (-1.09%)
Market Cap: 728.77 Tn
Enterprise Value: 755.05 Tn
PE Ratio: 86.20
PB Ratio: 50.39
GF Score: 64/100 Eli Lilly and Co at Cowen Healthcare Conference (Virtual) Transcript
Mar 04, 2021 / 02:10PM GMT
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good morning and welcome to the Eli Lilly's session of Cowen's 41st Annual Healthcare Conference. We're very pleased to have with us today, Dr. Dan Skovronsky, who is Senior Vice President and Chief Scientific Officer.
Cowen has been recommending Lilly's stock now since 2014, and it has been a great stock because great companies tend to be great stocks. And great companies are led by great leaders. And we have one of those great leaders here today. So Dan, thank you for your time.
Daniel M. Skovronsky
Eli Lilly and Company - Senior VP, Chief Scientific Officer & President of Lilly Research Labs
Thank you, Steve.
Questions & Answers
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Maybe we could start out by talking about tirzepatide because of the data that was just issued this morning, the SURPASS-2 data. Maybe you could just take a moment to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot